Pleiotropic effects of thiazolidinediones (Q37142044)

18 August 2017

1 reference

title

Pleiotropic effects of thiazolidinediones (English)

1 reference

18 August 2017

1 reference

Evangelos N Liberopoulos

0 references

author name string

C V Rizos

1

1 reference

18 August 2017

E N Liberopoulos

2

1 reference

18 August 2017

D P Mikhailidis

3

1 reference

18 August 2017

M S Elisaf

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

Expert Opinion on Pharmacotherapy

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

7

1 reference

18 August 2017

page(s)

1087-1108

1 reference

Epidemic obesity and type 2 diabetes in Asia

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The peroxisome proliferator-activated receptors: ligands and activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptor gamma and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Troglitazone-induced liver failure: a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Progression to clinically diagnosed and treated diabetes from impaired glucose tolerance and impaired fasting glycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Beta-cell preservation with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Adiponectin and protection against type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Does rosiglitazone adversely affect bone formation and bone mineral density in postmenopausal women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of thiazolidinediones on bone loss and fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Metformin as a cause of late-onset chronic diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of thiazolidinediones on body weight in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The long-term effects of rosiglitazone on serum lipid concentrations and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Insulin resistance and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Dyslipidaemia, hypercoagulability and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pioglitazone improves left ventricular diastolic function in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Rosiglitazone Lowers Blood Pressure and Increases Arterial Compliance in Postmenopausal Women With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of insulin on renal sodium and uric acid handling in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Statins: another class of antihypertensive agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Analysis of antihypertensive effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Insulin resistance and risk of chronic kidney disease in nondiabetic US adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Resistin is an inflammatory marker of atherosclerosis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Platelet dysfunction in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Laboratory markers of platelet activation and their clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Insulin resistance as a determinant of platelet activation in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Interleukin 6 and haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improvement of liver function parameters in patients with type 2 diabetes treated with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Endothelial dysfunction as an early sign of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The prevalence and features of the polycystic ovary syndrome in an unselected population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Thiazolidinedione use and post-operative atrial fibrillation: a US nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Do statins have an antiarrhythmic activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Adipokines and Risk of Type 2 Diabetes in Older Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.7.1087

10.1517/14656566.9.7.1087

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference